<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM&nbsp;8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT PURSUANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TO SECTION&nbsp;13 OR 15(D)&nbsp;OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):&nbsp;<B>&nbsp;August
6, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Interleukin Genetics,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant as Specified in
Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Delaware</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(State or Other Jurisdiction of Incorporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 49%; vertical-align: top; font-weight: bold; text-align: center">001-32715</TD>
    <TD STYLE="width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 49%; vertical-align: top; font-weight: bold; text-align: center">94-3123681</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">(Commission File Number)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">(IRS Employer Identification No.)</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">135 Beaver Street Waltham, MA</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">02452</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">(Address of Principal Executive Offices)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(781) 398-0700</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant&rsquo;s Telephone Number, Including
Area Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former Name or Former Address, if Changed
Since Last Report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Check the appropriate box below if the Form&nbsp;8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see
</I>General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Written communications pursuant to Rule&nbsp;425 under
the Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Soliciting material pursuant to Rule&nbsp;14a-12 under
the Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under
the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under
the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 5.02</B></TD><TD><B>Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
August 7, 2012, at the 2012 Annual Meeting of Shareholders (the &ldquo;Annual Meeting&rdquo;) of Interleukin Genetics, Inc. (the
&ldquo;Company&rdquo;), the shareholders approved the Company&rsquo;s 2012 Employee Stock Purchase Plan (the &ldquo;Purchase Plan&rdquo;),
as described under Proposal 3 of Item 5.07 below. The Purchase Plan provides eligible employees with the opportunity to purchase
up to 750,000 shares of the Company&rsquo;s common stock, at a discount, on a tax-favored basis through payroll deductions in compliance
with Section 423 of the Internal Revenue Code of 1986, as amended. The Purchase Plan replaces the Company&rsquo;s outstanding Employee
Stock Purchase Plan which was terminated as almost all shares thereunder had been issued as of March 31, 2012. &nbsp;A description
of the terms and conditions of the Purchase Plan is set forth in the Company&rsquo;s definitive Proxy Statement on Schedule 14A
filed with the Securities and Exchange Commission on June 22, 2012 under the heading &ldquo;Proposal 3: Approval of the 2012 Employee
Stock Purchase Plan,&rdquo; and is incorporated herein by reference. Such description is qualified in its entirety by reference
to the actual terms of the Purchase Plan, a copy of which is filed as Exhibit 10.1 to this Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 5.03</B></TD><TD><B>Amendment to Articles of Incorporation or Bylaws;
Change in Fiscal Year.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 9, 2012, the Company filed a certificate of amendment
with the Delaware Secretary of State to increase the number of the Company&rsquo;s authorized shares of common stock from 100,000,000
shares to 150,000,000 shares. The certificate of amendment became effective upon filing. A copy of the certificate of amendment
is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 5.07</B></TD><TD><B>Submission of Matters to a Vote of Security Holders.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company held its Annual Meeting&nbsp;on August 7, 2012.&nbsp;&nbsp;Holders
of 32,450,326 shares of the Company&rsquo;s common stock and 5,000,000 shares of the Company&rsquo;s Series A preferred stock (the
&ldquo;Preferred Stock&rdquo;) were present in person or by proxy.&nbsp;&nbsp;Each share of the Preferred Stock is convertible
into approximately 5.63 shares of the Company&rsquo;s common stock and is entitled to one vote for each share of common stock into
which it is convertible.&nbsp;&nbsp;Accordingly, shares representing 93.35% of the aggregate voting power were present in person
or by proxy at the Annual Meeting.&nbsp;&nbsp;The following are the results of the three proposals voted on at the Annual Meeting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Proposal 1</U>:&nbsp;&nbsp;Mary E. Chowning was elected to
serve as a Class III director for a three-year term expiring at the Company&rsquo;s 2015 annual meeting of shareholders.&nbsp;&nbsp;The
following chart shows the number of votes cast for the election of Ms. Chowning, as well as the number of votes withheld:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; width: 90%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 20%; font-weight: bold; text-decoration: underline">For</TD>
    <TD STYLE="width: 20%; font-weight: bold; text-decoration: underline">Withheld</TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Common Stock</TD>
    <TD>10,116,593</TD>
    <TD>647,019</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Preferred Stock</TD>
    <TD>5,000,000</TD>
    <TD>0</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, there were 21,686,714 broker
non-votes on Proposal 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Proposal 2</U>:&nbsp;&nbsp;The appointment of Grant Thornton
LLP as the Company&rsquo;s independent public accounting firm for the fiscal year ending December&nbsp;31, 2012 was ratified by
the shareholders.&nbsp;&nbsp;The following chart shows the number of votes cast for and against this proposal, as well as the number
of votes that abstained:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; width: 90%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 20%; font-weight: bold; text-decoration: underline">For</TD>
    <TD STYLE="width: 20%; font-weight: bold; text-decoration: underline">Against</TD>
    <TD STYLE="width: 20%; font-weight: bold; text-decoration: underline">Abstain</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Common Stock</TD>
    <TD>31,009,230</TD>
    <TD>76,038</TD>
    <TD>1,365,058</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Preferred Stock</TD>
    <TD>5,000,000</TD>
    <TD>0</TD>
    <TD>0</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Proposal 3</U>:&nbsp;&nbsp;The proposal to approve the Company&rsquo;s
2012 Employee Stock Purchase Plan was approved by the shareholders.&nbsp;&nbsp;The following chart shows the number of votes cast
for and against this proposal, as well as the number of votes that abstained:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; width: 90%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 20%; font-weight: bold; text-decoration: underline">For</TD>
    <TD STYLE="width: 20%; font-weight: bold; text-decoration: underline">Against</TD>
    <TD STYLE="width: 20%; font-weight: bold; text-decoration: underline">Abstain</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Common Stock</TD>
    <TD>10,303,314</TD>
    <TD>246,100</TD>
    <TD>214,198</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Preferred Stock</TD>
    <TD>5,000,000</TD>
    <TD>0</TD>
    <TD>0</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, there were 21,686,714 broker
non-votes on Proposal 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Proposal 4</U>:&nbsp;&nbsp;The proposal to increase the number
of the authorized shares of the Company&rsquo;s common stock from 100,000,000 shares to 150,000,000 shares was approved by the
shareholders.&nbsp;&nbsp;The following chart shows the number of votes cast for and against this proposal, as well as the number
of votes that abstained:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; width: 90%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 20%; font-weight: bold; text-decoration: underline">For</TD>
    <TD STYLE="width: 20%; font-weight: bold; text-decoration: underline">Against</TD>
    <TD STYLE="width: 20%; font-weight: bold; text-decoration: underline">Abstain</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Common Stock</TD>
    <TD>29,116,875</TD>
    <TD>2,889,244</TD>
    <TD>444,207</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Preferred Stock</TD>
    <TD>5,000,000</TD>
    <TD>0</TD>
    <TD>0</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 8.01</B></TD><TD><B>Other Events.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 6, 2012, the Company issued a press release announcing
the preliminary, top line results that the Company has received from the Periodontal Disease Prevention Study (PDPS) being conducted
by the University of Michigan School of Dentistry. The preliminary results indicate that in Low Risk patients, there was no significant
difference between two dental preventive visits per year and one preventive visit per year in reducing the percentage of patients
who had tooth extractions over the 16 year monitoring period; 13.8% versus 16.4% (p=0.092 ns). In addition, the preliminary results
indicate that in High Risk patients, two preventive visits per year significantly reduced the percentage of patients who had extractions
over a 16 year monitoring period compared to one preventive visit per year; 16.9% vs. 22.1% (p=0.002). There was also a positive
relationship between number of risk factors and the percentage of patients with extractions (p&lt;0.001). The Low Risk population
(approximately 47% of the study) was defined as non-smokers, genetically negative per the Company&rsquo;s PST test and no history
of diabetes. High Risk patients were defined as having one or more risk factors, i.e. PST positive, diabetes or smoking.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD>Exhibits</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">3.1</TD><TD>Certificate of Amendment filed with the Delaware Secretary
of State on August 9, 2012.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">10.1+</TD><TD>Interleukin Genetics, Inc. 2012 Employee Stock Purchase
Plan (incorporated by reference to Exhibit A of the Definitive Proxy Statement of Interleukin Genetics, Inc. filed on June 22,
2012).</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">99.1</TD><TD>Press Release dated August 6, 2012.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(+) Management contract or compensatory plan arrangement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">INTERLEUKIN GENETICS, INC.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">Date: August 9, 2012</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%">/s/ Eliot M. Lurier</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Eliot M. Lurier<BR>Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v320892_8k.htm", "description": "CURRENT REPORT", "secsgml_size_bytes": 25034}]
{"company-data": {"conformed-name": "INTERLEUKIN GENETICS INC", "cik": "0001037649", "assigned-sic": "2835", "irs-number": "943123681", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-32715", "film-number": "121020631"}, "business-address": {"street1": "135 BEAVER ST", "city": "WATHAM", "state": "MA", "zip": "02452", "phone": "1-781-398-0700"}, "mail-address": {"street1": "135 BEAVER ST", "city": "WATHAM", "state": "MA", "zip": "02452"}, "former-company": {"former-conformed-name": "MEDICAL SCIENCE SYSTEMS INC", "date-changed": "19971003"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
August
6, 2012
Interleukin Genetics, Inc.
(Exact Name of Registrant as Specified in
Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
001-32715
94-3123681
(Commission File Number)
(IRS Employer Identification No.)
135 Beaver Street Waltham, MA
02452
(Address of Principal Executive Offices)
(Zip Code)
(781) 398-0700
(Registrant's Telephone Number, Including
Area Code)
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02
Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e)           On
August 7, 2012, at the 2012 Annual Meeting of Shareholders (the "Annual Meeting") of Interleukin Genetics, Inc. (the
"Company"), the shareholders approved the Company's 2012 Employee Stock Purchase Plan (the "Purchase Plan"),
as described under Proposal 3 of Item 5.07 below. The Purchase Plan provides eligible employees with the opportunity to purchase
up to 750,000 shares of the Company's common stock, at a discount, on a tax-favored basis through payroll deductions in compliance
with Section 423 of the Internal Revenue Code of 1986, as amended. The Purchase Plan replaces the Company's outstanding Employee
Stock Purchase Plan which was terminated as almost all shares thereunder had been issued as of March 31, 2012.  A description
of the terms and conditions of the Purchase Plan is set forth in the Company's definitive Proxy Statement on Schedule 14A
filed with the Securities and Exchange Commission on June 22, 2012 under the heading "Proposal 3: Approval of the 2012 Employee
Stock Purchase Plan," and is incorporated herein by reference. Such description is qualified in its entirety by reference
to the actual terms of the Purchase Plan, a copy of which is filed as Exhibit 10.1 to this Form 8-K.
Item 5.03
Amendment to Articles of Incorporation or Bylaws;
Change in Fiscal Year.
On August 9, 2012, the Company filed a certificate of amendment
with the Delaware Secretary of State to increase the number of the Company's authorized shares of common stock from 100,000,000
shares to 150,000,000 shares. The certificate of amendment became effective upon filing. A copy of the certificate of amendment
is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 5.07
Submission of Matters to a Vote of Security Holders.
The Company held its Annual Meeting on August 7, 2012.  Holders
of 32,450,326 shares of the Company's common stock and 5,000,000 shares of the Company's Series A preferred stock (the
"Preferred Stock") were present in person or by proxy.  Each share of the Preferred Stock is convertible
into approximately 5.63 shares of the Company's common stock and is entitled to one vote for each share of common stock into
which it is convertible.  Accordingly, shares representing 93.35% of the aggregate voting power were present in person
or by proxy at the Annual Meeting.  The following are the results of the three proposals voted on at the Annual Meeting:
Proposal 1
:  Mary E. Chowning was elected to
serve as a Class III director for a three-year term expiring at the Company's 2015 annual meeting of shareholders.  The
following chart shows the number of votes cast for the election of Ms. Chowning, as well as the number of votes withheld:
For
Withheld
Common Stock
10,116,593
647,019
Preferred Stock
5,000,000
0
In addition, there were 21,686,714 broker
non-votes on Proposal 1.
Proposal 2
:  The appointment of Grant Thornton
LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2012 was ratified by
the shareholders.  The following chart shows the number of votes cast for and against this proposal, as well as the number
of votes that abstained:
For
Against
Abstain
Common Stock
31,009,230
76,038
1,365,058
Preferred Stock
5,000,000
0
0
Proposal 3
:  The proposal to approve the Company's
2012 Employee Stock Purchase Plan was approved by the shareholders.  The following chart shows the number of votes cast
for and against this proposal, as well as the number of votes that abstained:
For
Against
Abstain
Common Stock
10,303,314
246,100
214,198
Preferred Stock
5,000,000
0
0
In addition, there were 21,686,714 broker
non-votes on Proposal 3.
Proposal 4
:  The proposal to increase the number
of the authorized shares of the Company's common stock from 100,000,000 shares to 150,000,000 shares was approved by the
shareholders.  The following chart shows the number of votes cast for and against this proposal, as well as the number
of votes that abstained:
For
Against
Abstain
Common Stock
29,116,875
2,889,244
444,207
Preferred Stock
5,000,000
0
0
Item 8.01
Other Events.
On August 6, 2012, the Company issued a press release announcing
the preliminary, top line results that the Company has received from the Periodontal Disease Prevention Study (PDPS) being conducted
by the University of Michigan School of Dentistry. The preliminary results indicate that in Low Risk patients, there was no significant
difference between two dental preventive visits per year and one preventive visit per year in reducing the percentage of patients
who had tooth extractions over the 16 year monitoring period; 13.8% versus 16.4% (p=0.092 ns). In addition, the preliminary results
indicate that in High Risk patients, two preventive visits per year significantly reduced the percentage of patients who had extractions
over a 16 year monitoring period compared to one preventive visit per year; 16.9% vs. 22.1% (p=0.002). There was also a positive
relationship between number of risk factors and the percentage of patients with extractions (p<0.001). The Low Risk population
(approximately 47% of the study) was defined as non-smokers, genetically negative per the Company's PST test and no history
of diabetes. High Risk patients were defined as having one or more risk factors, i.e. PST positive, diabetes or smoking.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits
3.1
Certificate of Amendment filed with the Delaware Secretary
of State on August 9, 2012.
10.1+
Interleukin Genetics, Inc. 2012 Employee Stock Purchase
Plan (incorporated by reference to Exhibit A of the Definitive Proxy Statement of Interleukin Genetics, Inc. filed on June 22,
2012).
99.1
Press Release dated August 6, 2012.
(+) Management contract or compensatory plan arrangement
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INTERLEUKIN GENETICS, INC.
Date: August 9, 2012
/s/ Eliot M. Lurier
Eliot M. Lurier
Chief Financial Officer